Acuta Capital Partners’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-580,000
| Closed | -$3.96M | – | 44 |
|
|
2022
Q1 | $3.96M | Buy |
+580,000
| New | +$3.96M | 1.85% | 18 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 39 |
|
|
2021
Q3 | – | Sell |
-561,011
| Closed | -$3.78M | – | 49 |
|
|
2021
Q2 | $3.78M | Sell |
561,011
-533,989
| -49% | -$3.59M | 1.51% | 23 |
|
|
2021
Q1 | $9.9M | Buy |
1,095,000
+389,782
| +55% | +$3.52M | 3.57% | 4 |
|
|
2020
Q4 | $4.71M | Hold |
705,218
| – | – | 1.28% | 29 |
|
|
2020
Q3 | $3.55M | Sell |
705,218
-1,047,000
| -60% | -$5.28M | 0.97% | 29 |
|
|
2020
Q2 | $14.2M | Sell |
1,752,218
-921,500
| -34% | -$7.45M | 4.09% | 7 |
|
|
2020
Q1 | $20.9M | Buy |
2,673,718
+1,048,718
| +65% | +$8.22M | 10.15% | 1 |
|
|
2019
Q4 | $12.3M | Buy |
+1,625,000
| New | +$12.3M | 3.04% | 9 |
|